Table 5.

Correlation of host hepatic tumour necrosis with clinicopathological characteristics of the patients undergoing liver transplantation for hepatocellular carcinoma.

Variable	Without TACE			With TACE
	Necrosis+	Necrosis−	p	Necrosis+	Necrosis−	p
No. of patients		9	24	46	9
Age
≤60	5 (55.6%)	9 (37.5%)	0.350	21 (45.7%)	2 (22.2%)	0.193
<60	4 (44.4%)	15 (62.5%)		25 (54.3%)	7 (77.8%)
Gender
Male	7 (77.8%)	19 (79.2%)	0.931	39 (84.8%)	8 (88.9%)	0.749
Female	2 (22.2%)	5 (20.8%)		7 (15.2%)	1 (11.1%)
Graft tumour recurrence
Positive	2 (22.2%)	3 (12.5%)	0.488	3 (6.5%)	3 (33.3%)	0.018
Negative	7 (77.8%)	21 (87.5%)		43 (93.5%)	6 (66.7%)
Distant metastases
Positive	2 (22.2%)	2 (8.3%)	0.276	6 (13.0%)	3 (33.3%)	0.132
6Negative	7 (77.8%)	22 (91.7%)		40 (87.0%)	6 (66.7%)
Graft rejection
With	4 (44.4%)	12 (50.0%)	0.776	12 (26.1%)	1 (11.1%)	0.333
Without	5 (55.6%)	12 (50.0%)		34 (73.9%)	8 (88.9%)
Tumour size, mm
≤20	3 (33.3%)	16 (66.7%)	0.084	35 (76.1%)	9 (100.0%)	0.101
>20	6 (66.7%)	8 (33.3%)		11 (23.9%)	0 (00.0%)
Angioinvasion
Positive	2 (22.2%)	2 (8.3%)	0.276	6 (13.0%)	0 (00.0%)	0.251
Negative	7 (77.8%)	22 (91.7%)		40 (87.0%)	9 (100.0%)
Lymphangiosis carcinomatosa
Positive	0 (0.0%)	1 (4.2%)	0.534	6 (13.0%)	1 (11.1%)	0.874
Negative	9 (100.0%)	23 (95.8%)		40 (87.0%)	8 (88.9%)
Histologic differentiation
G1 well	3 (33.3%)	12 (50.0%)	0.392	25 (54.3%)	4 (44.4%)	0.586
G2 moderate/G3 poor	6 (66.7%)	12 (50.0%)		21 (45.7%)	5 (55.6%)
Pathologic T stage
T1	6 (66.7%)	22 (91.7%)	0.074	26 (56.5%)	1 (11.1%)	0.013
T2/T3	3 (33.3%)	2 (8.3%)		20 (43.5%)	8 (88.9%)
CD163+ TAMs in TCA
Positive	4 (44.4%)	15 (62.5%)	0.350	21 (45.7%)	8 (88.9%)	0.018
Negative	5 (55.6%)	9 (37.5%)		25 (54.3%)	1 (11.1%)
Angiopoietin-1/TIF
Positive	8 (88.9%)	11 (45.8%)	0.026	31 (67.4%)	7 (77.8%)	0.537
Negative	1 (11.1%)	13 (54.2%)		15 (32.6%)	2 (22.2%)